Prior to that, Crouse held a COO position at Immucor. Crouse previously served as CEO of Cord Blood Registry, which was sold to AMAG Pharmaceuticals. Syneron Candela said today that its approximately $400 million sale to private equity fund Apax Partners closed today, and that it is now functioning as a privately held company under Apax.Īpax Partners paid $11 per share in cash for Syneron, with shares ceasing trading on the Nasdaq Stock Market this morning and the company delisting from the market.Īs part of the transaction, Apax Partners has appointed Geoffrey Crouse as CEO and board member of Syneron. The definitive proxy statement (when available) may be obtained for free at the SEC's website at In addition, the definitive proxy statement will be available, without charge, at Syneron Candela’s website at. Shareholders are urged to carefully read the definitive proxy statement and other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. Shareholders of Syneron Candela are urged to read the definitive proxy statement and the other relevant material when they become available because they will contain important information about Syneron Candela, Apax Partners, the proposed transaction and related matters. It will mail a definitive proxy statement and proxy card to its shareholders and furnish a copy of those materials to the SEC on Form 6-K. In connection with the proposed transaction, Syneron Candela filed a preliminary proxy statement on Form 6-K with the SEC. The statements made by the Company are based upon management's current expectations and the Company undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this release except as required by law. Additional information regarding these and other factors is contained in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F. Achievement of these results by the Company may be affected by many factors, including, but not limited to, risks and uncertainties regarding the ability to close the proposed transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties' ability to satisfy certain closing conditions, including shareholder and regulatory approvals; the risk that the benefits of the potential transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers the risk that the Company's business may not perform as expected as well as general economic conditions. Such "forward looking statements" involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. Such forward-looking statements include statements regarding the expected timing of the proposed acquisition. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |